NRC
National Research Corp.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$25.16
+4.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 143.8M | 137.4M | 143.1M | 148.6M | 151.6M |
| Cost of Revenue | 75.0M | 60.0M | 56.9M | 56.0M | 57.0M |
| Gross Profit | 68.8M | 77.4M | 86.1M | 92.6M | 94.5M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 50.8M | 54.8M | 44.9M | 46.6M | 42.7M |
| General & Admin Expense | 22.9M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.1M | — | 6.0M | 5.9M | 5.3M |
| Total Operating Expenses | 52.9M | 54.8M | 50.9M | 52.5M | 48.0M |
| Cost and Expenses | 127.9M | 114.8M | 107.9M | 108.5M | 105.0M |
| Operating Income (EBIT) | 15.9M | 22.6M | 35.2M | 40.0M | 46.5M |
| Non-Operating | |||||
| Interest Income | 111.0K | 111.0K | 125.0K | 820.0K | 168.0K |
| Interest Expense | 5.5M | 4.8M | 2.6M | 862.0K | 1.2M |
| Net Interest Income | (5.4M) | (4.7M) | (2.5M) | (42.0K) | (1.0M) |
| Other Non-Op Income/Expense | (5.4M) | (4.7M) | (2.5M) | (83.0K) | (3.7M) |
| Non-Operating Income (excl Interest) | (82.0K) | (16.0K) | (91.0K) | (41.0K) | 2.5M |
| EBT (Pre-Tax Income) | 10.5M | 17.8M | 32.7M | 40.0M | 42.8M |
| Income Tax Expense | 4.1M | 6.2M | 7.9M | 9.0M | 11.0M |
| Bottom Line | |||||
| Net Income | 6.4M | 11.6M | 24.8M | 31.0M | 31.8M |
| Earnings from Cont. Ops | 6.4M | 11.6M | 24.8M | 31.0M | 31.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 6.4M | 11.6M | 24.8M | 31.0M | 31.8M |
| Per Share | |||||
| Basic EPS | $0.30 | $0.52 | $1.05 | $1.26 | $1.28 |
| Diluted EPS | $0.28 | $0.52 | $1.04 | $1.25 | $1.27 |
| Revenue Per Share | $6.62 | $6.14 | $6.03 | $6.05 | $6.08 |
| Shares | |||||
| Basic Shares Outstanding | 21.7M | 22.4M | 23.7M | 24.5M | 24.9M |
| Diluted Shares Outstanding | 21.9M | 22.4M | 23.7M | 24.7M | 25.1M |
| Profitability Metrics | |||||
| EBITDA | 24.5M | 30.2M | 41.3M | 46.0M | 49.3M |
| D&A | 8.5M | 7.6M | 6.0M | 5.9M | 5.3M |
| EBIT | 16.0M | 22.6M | 35.3M | 40.1M | 44.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026